Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Saturday, January 30, 2010

Multiple Sclerosis risk, changes with the seasons

Highs and Lows of when MS with the seasons .. Is this what they are now saying?

Washington, Jan 30 : A new study has revealed that the risk of developing multiple sclerosis changes with the season.

Lead researchers Emmanuelle Waubant and Ellen Mowry revealed that this seasonal effect is mediated by gene HLA-DRB1.

In many European populations, the HLA-DRB1*15 allele of this gene is associated with an increased risk of MS, and the large-scale study of MS patients from Canada, Sweden and Norway now shows that this allele is more common among patients born in the spring.

The researchers said the study was "unique in its attempt to understand how genes and environment interact in MS".

They said Vitamin D appears to influence the expression of the HLA-DRB1*15 allele.

Since vitamin D production fluctuates with the seasons, a vitamin D deficit in pregnant mothers could be related to the increased risk of MS among spring births.

However, further studies are required.

Waubant and Mowry said that understanding the environmental risks and their interaction with relevant genotypes might pave way for new treatments.

Study author Dr Sreeram Ramagopalan said that taking vitamin D supplements during pregnancy may reduce the risk of a child developing MS in later life.

Government guidelines also recommend that childrenunder five take daily vitamin D supplements.

The findings appear in journal Neurology.

--ANI


Article source: newKerala.com

######################

.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

============================================

Friday, January 29, 2010

Could stem cells reverse MS?

January 28th, 2010

(PhysOrg.com) -- Biologist Tom Lane and a team of UCI researchers are leading an effort to determine whether a stem-cell-based treatment can repair neurological damage caused by multiple sclerosis.

More than eight years ago, Tom Lane helped discover a potential way to prevent multiple sclerosis from affecting the central nervous system. Now he’s leading an effort at UC Irvine to determine whether a stem-cell-based treatment can repair neurological damage caused by the chronic disease.

Lane, a molecular biology & biochemistry professor, is among 15 U.S. researchers who recently received five-year Collaborative MS Research Center Awards from the National Multiple Sclerosis Society. With the $742,500 in funding, he has assembled a team to investigate the use of cell-replacement therapy to regenerate MS-ravaged nerve tissue.

In people with MS, immune-system T cells attack myelin, the protective coating of nerves, and eventually the nerve fibers themselves. Symptoms may be mild, such as intermittent numbness in the limbs, or severe, such as paralysis or loss of vision. There is no cure for MS, and current treatments mainly try to limit immune-system response.

“The promise of cell-replacement strategies to treat MS is significant,” Lane says. “Imagine being able to infuse people with cells that could make new myelin or transform into healthy nerve cells. That’s the focus of our effort.”


Continue to read by clicking here


######################

.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

============================================

Benefits of Tysabri far outweigh risks, European watchdog group says about Multiple Sclerosis drug


Tysabri is given by infusion
Tysabri is given by infusion
NMMS

January 26, 9:43 PMMultiple Sclerosis ExaminerMike Szymanski

A drug watchdog group in Europe has offered a thumbs-up for the Multiple Sclerosis drug Tysabri, as Europeans consider restricting the medication.

A short-term review of the drug by the European Medicines Agency noted that the benefits of the medication, usually given by infusion, is far better than the risk of the brain disease,progressive multifocal leukoencephalopathy (PML). The rare brain infection has been noted in patients taking the drug more than two years.

The European distributors of the medication are considering stronger warning labels for people taking Tysabri.

The latest reports note that 31 patients on Tysabri have contracted a rare brain disease, 23 of them were on the medication for more than two years, and that puts the risk rate at 1 in 1,000.

The committee report notes that after two years, the risk of Tysabri increases, but it is still minimal for people with active relapsing-remitting MS.

Link to article at the Examiner.com
.

######################

.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

============================================

Biologist launches stem cell test to cure Multiple Sclerosis symptoms

January 28, 5:46 PMMultiple Sclerosis ExaminerMike Szymanski

A California biologist is launching a study to see how stem cells may reverse the effects of Multiple Sclerosis.

The hope by molecular biologist Thomas E. Lane and the University of California at Irvine scientific team, is that the stem-cell treatment can repair damage to the myelin and nerves that are damaged by the neurological disease.

"The promise of cell-replacement strategies to treat MS is significant," Lane is quoted in a UC Irvine press release issued Thursday (Jan. 28). "Imagine being able to infuse people with cells that could make new myelin or transform into healthy nerve cells. That's the focus of our effort."

He is one of 15 scientists who won a grant of $742,500 funding from the Collaborative MS Research Center Awards from the National Multiple Sclerosis Society.

Lane discovered a way to prevent the illness from damaging the central nervous system, and now he is working with stem cells.

With MS, the T-cells in the immune system of the body attack the myelin, which is the protective coating of the nerves. The T-cells also attack the nerve fibers and results in numbness of the limbs, paralysis, loss of vision and other symptoms.

A number of other studies at UC Irvine are also being funded to help study MS.

"With the knowledge acquired from these studies, we believe we’ll lay the foundation for the creation of safe and effective treatments to improve quality of life for people with MS," Lane says. "UCI has long been a leader in MS research and patient care, and it’s exciting to be part of the significant impact our researchers and clinicians make in this field."

Article Source: CLICK

######################

.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

============================================

Thursday, January 28, 2010

Italian group offers $4.5M to fund new MS research on CCSVI ("Chronic cerebro-spinal venous insufficiency")

Avis Favaro, CTV Medical Specialist

Date: Wednesday Jan. 27, 2010 5:53 PM ET

The Italian Multiple Sclerosis Foundation today announced it will allocate up to $4.5 million to fund ongoing research into CCSVI, a condition linked to Multiple Sclerosis.

The foundation says it is accepting research proposals until March 8 from scientists interested in studying "chronic cerebro-spinal venous insufficiency," a newly-discovered condition uncovered by a team at the University of Ferrara in Italy and lead scientist Dr. Paolo Zamboni.

“We await proposals from groups of Italian researchers, in particular by the research groups that are already active with Prof. Zamboni,” the foundation said in an Italian news release.

Zamboni's team believes that CCSVI causes veins in the neck and upper chest to twist, narrow or become blocked; in some cases, these veins never form at all. The result is poor blood drainage from the brain. Zamboni has found that more than 90 per cent of patients with MS have these malformed veins, and improper blood flow from the brain.

Roberta Amaedo, president of the Italian Association for Multiple Sclerosis, said in the release: "We need certainty about the relationship between MS and CCSVI and on the clinical course that this can cause, and on that, clinical trials will make an important contribution.”

The association also cautioned patients against seeking endovascular or surgical procedures to open these blocked veins outside of controlled research studies.


Continue reading a watch a video by clicking here

######################

.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

============================================

Wednesday, January 27, 2010

Biogen Starts Human Trial For Drug That Could Repair MS Damage

Info for this article provided to me by Rusty...


By Thomas Gryta and Jon Kamp, Of DOW JONES NEWSWIRES

NEW YORK -(Dow Jones)- Biogen Idec Inc. (BIIB) has begin human testing of an experimental drug, dubbed BIIB033, that it hopes will take the revolutionary step of repairing some of the damage done by multiple sclerosis.

Although it is a major step to begin testing in humans, drug development is always risky and it will take years to measure the drug's effectiveness and potential side effects.

Multiple sclerosis, or MS, is a chronic, inflammatory condition that occurs when the body attacks its own myelin, the protective insulation surrounding the nerve fibers, or axons, in the central nervous system. The debilitating disease affects an estimated 400,000 people in the U.S., according to the National MS Society, but current treatments only aim to slow the disease's progression and cannot help repair damage.

Research that focuses on ways to help the body regenerate myelin is growing and scientists around the world are taking several different approaches. Damage to myelin can distort or block messages carried by axons and result in a wide variety of MS symptoms such as vision problems, limb numbness and paralysis.

BIIB033 is an antibody designed to turn off Lingo-1, a molecule that the company believes prevents myelin production in adults after axons are well covered. Blocking Lingo-1 may encourage myelin regeneration, something that occurs in healthy adults, after damage from MS occurs.

The antibody has been shown to be effective in mouse models that are accepted as being useful for mimicking the properties of MS.

Continue from: The small Phase I study - on Nasdaq.com


######################


.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

==================================

Coral Gables man turns to running to fight Multiple Sclerosis

Jose Rivas, who was diagnosed with multiple sclerosis five years ago, will run the ING Marathon on Sunday to help raise money for the National MS Society.

CTEPROFF@MIAMIHERALD.COM

Jose Rivas first realized something was wrong when he was sitting at his desk and suddenly felt as if he were falling.

Then, some time later, he started having moments when he would be reading but couldn't make out the words.

``It was a feeling I can't even describe,'' said Rivas, now 47.

The Coral Gables resident and financial advisor began seeing doctors. After 10 years, dozens of tests and a lot of patience, Rivas was diagnosed with multiple sclerosis, a neurological disease that interferes with communication between the brain and various parts of the body.

Rather than giving in to what could be a debilitating disease, Rivas said he wanted to take control of his health by staying in top physical shape.

So he turned to long-distance running.

Now, five-years later, Rivas will be running in the ING Miami Marathon on Sunday to raise money for the MS Society, to help doctors search for a cure for the ``terrible disease.''

``As soon as I was diagnosed I immediately became involved in the MS Society,'' said Rivas, who acknowledges his fears of one day ending up in a wheelchair. ``There is a lot of suffering out there.''

Rivas plans on running a half marathon, or 13.1 miles, in Sunday's race, which will draw about 18,000 participants -- many of whom are raising money for a variety of charities. The race begins at the AmericanAirlines Arena and takes runners over the MacArthur Causeway to South Beach, through the Venetian Islands, downtown Miami and Coconut Grove, and finishes at Bayfront Park.

``The race itself serves as a vehicle for charities to raise money for a number of causes,'' said Frankie Ruiz, co-founder of the ING Miami Marathon. ``There is a lot of money that is going to be raised as a result of the race.''

Rivas and his team of about 30 runners set a goal of $50,000. Rivas said they have already raised more than $40,000. Most of his teammates are relatives of people with MS.

Continue reading from the Miami Herald

######################

My Congratulations to Jose and others with MS that I know are running in this weekend's event.

Jose and I, at one time served on the National MS Society's Coral Gables MS Walk Committee. He deserves the recognition he received with the article shown above.
.

============================================

Why the US news media silence, on CCSVI for MS??

written by Marc Stecker (wheelchair kamikaze)- New York, USA

The topic of CCSVI, the radical new theory that MS may in fact be a vascular disease, has been raging on the Internet for several months now. On some prominent MS forums, the topic has bred near hysteria among contributors, and the websites of most of the major MS advocacy groups (the NMSS, the MSAA, etc.) have featured CCSVI information, with varying degrees of enthusiasm.

Outside of the US, CCSVI has been featured prominently in mainstream television and print news media outlets. In Canada, one of the major television networks aired a 20 minute long newsmagazine feature on CCSVI, and the pros and cons of the theory have been written about in many of the country's newspapers. The European news media have also devoted time to the theory, which got its start when the wife of an Italian vascular surgeon developed multiple sclerosis, and he investigated the blood vessels associated with her central nervous system, finding odd vascular abnormalities.

In the United States, though, the media have responded to this potentially groundbreaking theory with resounding silence. There have been no print articles about CCSVI in any major American newspaper, nor have any of the US television network news organizations paid it any notice. Very strange, given the breathless coverage many medical discoveries of lesser potential are given in the modern, voracious 24-hour news environment that demands a constant stream of newsworthy items and events. The "balloon boy" hoax was given countless hours of coverage; yet a story about a possible breakthrough in the fight against Multiple Sclerosis, a disease that affects hundreds of thousands of Americans, has warranted not even a whisper.

Continue to read directly from the Wheelchair Kamikaze's webpage

.

============================================

Tuesday, January 26, 2010

Opressors like Iron Overload and Oxidative Stress, leading to MS ?

Dr. Rudy Cartwight's descriptive information of

Dr. Zamboni’s Liberation Treatment for Multiple Sclerosis



If interested in listing to an MS Health Coach's audio on the cause for CCSVI, then click here: http://mshealthcoach.com/blog/ms-health-coaching/dr-zambonis-liberation-treatment-for-multiple-sclerosis/comment-page-1/#comment-63

This information was provided by Dianne in Pa.


######################

Is this More Media Frenzy on CCSVI being a precedent cause to MS?

Posted today on Facebook, this information was provided to me from Kimberly A., in Edmunton AB

Please read My opinion found in Red Print seen beneath this CCSVI release.

Consensus Conference on Venous Malformations - headed by Prof. Byung B Lee from Georgetown - and experts from 47 countries- studied the evidence and unanimously voted in favour of officially including the stenosing lesions found in CCSVI in the new Consensus document and Guidelines. Now published-

http://www.ncbi.nlm.nih.gov/pubmed/20087280?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1

This paper can be brought/linked to interventional radiologists and vascular surgeons. CCSVI lesions are classified as a truncular venous malformations - which means that vascular doctors have now classified this disease, CCSVI, as congenital- and preceding MS lesions.


Vascular doctors have agreed. CCSVI comes first.

Dr. Zamboni has been speaking to medical panels around the world. Yesterday was a "4 hour machine gunning of questions" by the Italian, Canadian and US MS Societies in Milan- Dr. Zamboni said he was able to answer all the questions with scientific evidence, and was quite pleased with the meeting's outcome. He'll be in North American soon.
=============================

The information found above is not authenticated or sanctioned by Stu's Views & MS News or MS Views and News. It is being provided as a courtesy for all with an interest in CCSVI research.

Additionally, I found that the information being released is based upon previous News.

Nothing new has gone into print since December ..
See this PubMed page of all found (to today's date) on CCSVI: http://www.ncbi.nlm.nih.gov/sites/entrez


I Believe (yes, this is my opinion) that It is being rebroadcast to re-arouse your attention on this matter.

Yes, I am the skeptic. Especially when Nothing (factually) New has been released to the media.

Geez though - I hope that I am wrong...


######################

.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

============================================

Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis

Info provided by Karen D in South Florida:

First Published Jan 20, 2010

MRI brain lesions at presentation with optic neuritis (ON) increase the risk for developing clinically definite (CD) multiple sclerosis (MS). More detailed early MRI findings may improve prediction of conversion.

The objectives of this study were to investigate the influence of number, location and activity of lesions at presentation, new lesions at early follow-up and non-lesion MRI measures on conversion from optic neuritis (ON) to CDMS.

142/143 ON patients, prospectively recruited into a serial MRI and clinical follow-up study, were followed-up at least once. Cox regression analysis determined independent early MRI predictors of time to CDMS from: (i) baseline lesion number, location and activity measures, (ii) three-month lesion activity measures and (iii)brain atrophy, magnetization transfer ratio and spectroscopy measures.

114/142 (80%) had abnormal baseline brain or cord MRI. 57 (40%) developed CDMS (median of 16 months from clinically isolated syndrome onset). Median follow-up of the non-converters was 62 months. Multivariate analysis of baseline parameters revealed gender, periventricular and gadolinium-enhancing lesions as independent predictors of CDMS. Considering both scans together, gender, baseline periventricular and new T2 lesions at follow-up remained significant (hazard ratios 2.1, 2.4 and 4.9, respectively). No non-conventional measure predicted CDMS.

It was concluded that new T2 lesions on an early follow-up scan were the strongest independent predictor of CDMS.

Multiple Sclerosis 2010, doi:10.1177/1352458509353650

Click here to review full content

.

######################

.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

============================================

Nurse takes cue from patients to raise awareness for MS

ST. LOUIS POST-DISPATCH

Michelle Keating is an oncology nurse whose patients inspired her to spread awareness for her own disease.

Keating, 53, has had multiple sclerosis for 29 years, but three days a week, her job at St. John's Mercy Medical Center is to provide information and support to people battling cancer.

When the cancer center started selling bracelets to benefit research, Keating suggested women in the support group craft their own.

"It was so successful, and the women had so much fun that I decided to try it with my MS support group," she said.
Continue Reading

######################

.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

============================================

Advancing Stem Cell Therapies for Multiple Sclerosis

UKSCF partners with MS Society-UK to financially support clinical development.

Susan Aldridge, Ph.D.

The UK Stem Cell Foundation (UKSCF) and theMultiple Sclerosis Society joined forces to accelerate the transfer of stem cell science into the clinic to help patients with multiple sclerosis (MS). Up to £1 million of seed funding is to be made available to applicants starting in September. The hope is to get Phase I/II trials of stem cells in MS under way over the next year or so, with initial results expected in 2012.

This is the first disease-specific collaboration for UKSCF, whose mission is to fund the gap between promising stem cell research and clinical trials. It was announced at a special meeting of the London Regenerative Medicine Network (LRMN) on January 14. “MS and advanced stem cell-based therapies—an ABC guide” was the first of a series of new disease-themed meetings to be hosted by LRMN.

Continue reading by clicking here, taking you to Genetic Engineering News

######################

.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

============================================

Monday, January 25, 2010

Multiple Sclerosis : Tysabri PML Updates Set to Start Again

Date Published: Monday, January 25th, 2010

The maker of Tysabri will once again provide monthly updates regarding new cases of progressive multifocal leukoencephalopathy, or PML, an often fatal brain infection seen in some people treated with the multiple sclerosis (MS) drug. Biogen Idec Inc. had stopped providing the monthly PML updates last summer.

Tysabri is seen as one of the most effective MS treatments on the market, especially for those with severe cases who have few other options. Unfortunately, it also poses serious risks because of its association with PML. PML attacks the brain and central nervous system and is usually fatal. It is caused by a polyomavirus, called the JC virus. The JC virus is often acquired during childhood. Most adults have been infected with the JC virus but do not develop PML. The virus appears to remain inactive until something (such as a weakened immune system) allows it to be reactivated and start to multiply. Symptoms include vision problems, loss of coordination, and memory loss. Patients who survive the disease are often permanently disabled.

In the U.S. Tysabri was taken off the market in 2005 after three patients in clinical trials developed PML. But the drug was reapproved in 2006, although it was subject to restrictions. Tysabri is now available only to patients with relapsing MS or Crohn’s Disease who are enrolled in the risk minimization plan called the TOUCH Prescribing Program. Under the TOUCH Prescribing Program, every Tysabri-treated patient is closely monitored and followed for the occurrence of PML and other serious opportunistic infections.

In September, the U.S. Food & Drug Administration (FDA) revealed that 24 cases of PML had been reported in Tysabri users, more than double the 11 Biogen Idec had disclosed at its final monthly update in July. As of mid-January, the number of PML cases among people treated with Tysabri stands at 31.

Continue to read from NewsInferno.com


######################

.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

============================================